Press Release Oct 02 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Enzalutamide Tablets in two dosages. These tablets are indicated for treating specific types of prostate cancer and will be manufactured at Zydus's facility in Ahmedabad. The press release highlights that the annual sales for Enzalutamide Tablets in the United States were significant, indicating a strong market potential.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 01 2024
- Press Release Sep 28 2024
- Press Release Sep 27 2024
- Press Release Sep 13 2024
- Press Release Sep 10 2024
Later from Zydus Lifesciences
- Press Release Oct 10 2024
- Press Release Oct 14 2024
- Press Release Oct 17 2024
- Press Release Oct 23 2024
- Press Release Nov 12 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences